Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases

Cited by (336)

Items 101–200 of 336

1. Metabolic primary liver cancer in adults: risk factors and pathogenic mechanisms
   Simonetta Lugari, Enrica Baldelli, Amedeo Lonardo · 2023 · Metabolism and Target Organ Damage
2. Brazilian evidence-based guideline for screening, diagnosis, treatment, and follow-up of metabolic dysfunction-associated steatotic liver disease (MASLD) in adult individuals with overweight or obesity: A joint position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Society of Hepatology (SBH), and Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso)
   Rodrigo O. Moreira, Cynthia Melissa Valério, Cristiane Alves Villela‐Nogueira, Cíntia Cercato, Fernando Gerchman, Ana Maria Lottenberg, Amélio F. Godoy‐Matos, Ricardo de Andrade Oliveira, Carlos Eduardo Brandão‐Mello, Mário Reis Álvares‐da‐Silva et al. · 2023 · Archives of Endocrinology and Metabolism
3. MASLD-Related HCC—Update on Pathogenesis and Current Treatment Options
   Catherine Leyh, Jason D. Coombes, Hartmut Schmidt, Ali E. Canbay, Paul Peter Manka, Jan Best · 2024 · Journal of Personalized Medicine
4. Etiology Exploration of Non-alcoholic Fatty Liver Disease From Traditional Chinese Medicine Constitution Perspective: A Cross-Sectional Study
   Ke Zhu, Yongsong Guo, Chenghao Zhao, Shixin Kang, Jialiang Li, Jiexin Wang, Zhaohui Tang, Bing Lin, Weihong Li · 2021 · Frontiers in Public Health
5. Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)
   Giulio Marchesini, Elisabetta Bugianesi, Patrizia Burra, Fabio Marra, Luca Miele, Anna Alisi, Piero Vajro, Mario Masarone, Salvatore Petta, Marcello Persico et al. · 2021 · Digestive and Liver Disease
6. Diabetes and Risk of Hepatocellular Carcinoma in Cirrhosis Patients with Nonalcoholic Fatty Liver Disease
   Pai‐Chi Teng, Daniel Q. Huang, Ting-Yi Lin, Mazen Noureddin, Ju Dong Yang · 2022 · Gut and Liver
7. MASLD-related HCC: Multicenter study comparing patients with and without cirrhosis
   Carole Vitellius, Elvire Desjonqueres, Marie Lequoy, Giuliana Amaddeo, Isabelle Fouchard, G. Nkontchou, Clémence M. Canivet, Marianne Ziol, Hélène Regnault, Adrien Lannes et al. · 2024 · JHEP Reports
8. TERT Promoter Mutation in Serum Cell-Free DNA Is a Diagnostic Marker of Primary Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease
   Norio Akuta, Yusuke Kawamura, Mariko Kobayashi, Yasuji Arase, Satoshi Saitoh, Shunichiro Fujiyama, Hitomi Sezaki, Tetsuya Hosaka, Masahiro Kobayashi, Yoshiyuki Suzuki et al. · 2020 · Oncology
9. A correlation study of the relationships between nonalcoholic fatty liver disease and serum triglyceride concentration after an oral fat tolerance test
   Xiaoyu Hou, Yunpeng Guan, Yong Tang, An Song, Jiajun Zhao, Luping Ren, Shuchun Chen, Limin Wei, Huijuan Ma, Guangyao Song · 2021 · Lipids in Health and Disease
10. Management of Diabetes in Candidates for Liver Transplantation and in Transplant Recipients
    Lucia Brodosi, Salvatore Petta, Maria Letizia Petroni, Giulio Marchesini, Maria Cristina Morelli · 2021 · Transplantation
11. Surveillance and diagnosis of hepatocellular carcinoma: A systematic review
    Sonia Pascual, Cayetano Miralles, Juan Matías Bernabé, Javier Irurzun, Mariana Cecilia Planells · 2019 · World Journal of Clinical Cases
12. Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease
    Luca V. C. Valenti, Federica Pedica, Massimo Colombo · 2021 · Digestive and Liver Disease
13. Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease
    Jimmy Che‐To Lai, Boyu Yang, Hye Won Lee, Huapeng Lin, Emmanuel A. Tsochatzis, Salvatore Petta, Elisabetta Bugianesi, Masato Yoneda, Ming‐Hua Zheng, Hannes Hagström et al. · 2025 · Gut
14. Public health strategies for hepatocellular carcinoma: from risk factors to prevention and control
    Mei-Hsuan Lee · 2025 · Journal of Liver Cancer
15. Expanding the Liver Imaging Reporting and Data System (LI-RADS) v2018 diagnostic population: performance and reliability of LI-RADS for distinguishing hepatocellular carcinoma (HCC) from non-HCC primary liver carcinoma in patients who do not meet strict LI-RADS high-risk criteria
    Daniel R. Ludwig, Tyler J. Fraum, Roberto Cannella, Richard Tsai, Muhammad Naeem, Maverick LeBlanc, Amber R. Salter, Allan Tsung, Jaquelyn Fleckenstein, Anup S. Shetty et al. · 2019 · HPB
16. Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease
    Karim Seif El Dahan, Darine Daher, Amit G. Singal · 2022 · Clinical and Molecular Hepatology
17. Effects of Cirrhosis and Diagnosis Scenario in Metabolic-Associated Fatty Liver Disease-Related Hepatocellular Carcinoma
    Vincent Lingzhi Chen, Ming‐Lun Yeh, Ju Dong Yang, Jennifer Leong, Daniel Q. Huang, Hidenori Toyoda, Yao‐Li Chen, Jennifer E. Guy, Mayumi Maeda, Pei‐Chien Tsai et al. · 2020 · Hepatology Communications
18. Changing the Treatment Paradigm for Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab Combination Therapy
    Masatoshi Kudo · 2021 · Cancers
19. Hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis
    Cristiane Valle Tovo, Ângelo Zambam de Mattos, Gabriela Perdomo Coral, Giovana Dal Pozzo SARTORI, Lívia Villela Nogueira, Gustavo Tovo Both, Cristiane Alves Villela‐Nogueira, Ângelo Alves de Mattos · 2023 · World Journal of Gastroenterology
20. Comparisons between non-alcoholic steatohepatitis and alcohol-related hepatocellular carcinoma
    Rahul Kumar, George Boon‐Bee Goh, Jia Wen Kam, Jason Pik-Eu Chang, Chee‐Kiat Tan · 2020 · Clinical and Molecular Hepatology
21. Targeting NTCP for liver disease treatment: A promising strategy
    X H Tan, Xiang Yu, Jianyou Shi, Lu Chen, Dongke Yu · 2024 · Journal of Pharmaceutical Analysis
22. Metabolically associated fatty liver disease – a disease of the 21st century: A review
    Igor Veniaminovich Maev, Д. Н. Андреев, Yu. A. Kucheryavyy · 2022 · Consilium Medicum
23. Dysfunctional VLDL metabolism in MASLD
    Urko M. Marigorta, Óscar Millet, Shelly Chi-Loo Lu, José María Mato · 2024 · npj Metabolic Health and Disease
24. Hepatocellular carcinoma and other complications of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in Japan: A structured review of published works
    Yuichiro Eguchi, Gabriel Wong, I‐Heng Lee, Omar Akhtar, Ricardo Lopes, Yoshio Sumida · 2020 · Hepatology Research
25. Global burden of nonalcoholic steatohepatitis-related liver cancer, 1990–2019: a systematic analysis for the GBD 2019
    Juan Pang, Ke Chen, Shen Chen, Xu Chen · 2022 · Diabetology & Metabolic Syndrome
26. Novel role for epalrestat: protecting against NLRP3 inflammasome-driven NASH by targeting aldose reductase
    Wei Shi, Guang Xu, Yuan Gao, Jun Zhao, Tingting Liu, Jia Wei Zhao, Huijie Yang, Ziying Wei, Hui Li, Anlong Xu et al. · 2023 · Journal of Translational Medicine
27. Emerging risk factors for nonalcoholic fatty liver disease associated hepatocellular carcinoma
    Jihane N. Benhammou, Jonathan Lin, Shehnaz K. Hussain, Mohamed M. El-Kabany · 2020 · Hepatoma Research
28. What Does the Future Hold for Patients With Nonalcoholic Steatohepatitis: Diagnostic Strategies and Treatment Options in 2021 and Beyond?
    Naim Alkhouri, Monica A. Tincopa, Rohit Seth Loomba, Stephen A. Harrison · 2021 · Hepatology Communications
29. Dysmetabolic comorbidities and non-alcoholic fatty liver disease: a stairway to metabolic dysfunction-associated steatotic liver disease
    Carmen Colaci, Maria Luisa Gambardella, Giuseppe Guido Maria Scarlata, Luigi Boccuto, Carmela Colica, Francesco Luzza, Emidio Scarpellini, Nahúm Méndez‐Sánchez, Ludovico Abenavoli · 2024 · Hepatoma Research
30. Retinoic Acid: A New Old Friend of IL-17A in the Immune Pathogeny of Liver Fibrosis
    Daria Kartasheva-Ebertz, Stanislas Pol, Sylvie Lagaye · 2021 · Frontiers in Immunology
31. Smad3 Phospho-Isoform Signaling in Nonalcoholic Steatohepatitis
    Takashi Yamaguchi, Katsunori Yoshida, Miki Murata, Kanehiko Suwa, Koichi Tsuneyama, Koichi Matsuzaki, Makoto Naganuma · 2022 · International Journal of Molecular Sciences
32. Pathogenesis from Inflammation to Cancer in NASH-Derived HCC
    Simiao Yu, Jingxiao Wang, Haocheng Zheng, Ruilin Wang, Nadia L. Johnson, Tao Li, Ping Li, Jie Lin, Yuan Li, Yan Jin et al. · 2022 · Journal of Hepatocellular Carcinoma
33. The Combination of MR Elastography and Proton Density Fat Fraction Improves Diagnosis of Nonalcoholic Steatohepatitis
    Salem Alsaqal, Paul D. Hockings, Håkan K. Ahlström, Anders Gummesson, Anders Hedström, Johannes Hulthe, Lars Johansson, Heiko G. Niessen, Corinna Schoelch, Christian Schultheis et al. · 2021 · Journal of Magnetic Resonance Imaging
34. Should we undertake surveillance for HCC in patients with MAFLD?
    Blanca Norero, Jean‐François Dufour · 2023 · Therapeutic Advances in Endocrinology and Metabolism
35. Prevalence of Low FIB‐4 in MASLD‐Related Hepatocellular Carcinoma: A Multicentre Study
    Darren Jun Hao Tan, Nobuharu Tamaki, Beom Kyung Kim, Karn Wijarnpreecha, Majd Bassam Aboona, Claire Faulkner, Charlotte Kench, Shirin Salimi, Abdul‐Hamid Sabih, Wen Hui Lim et al. · 2024 · Alimentary Pharmacology & Therapeutics
36. Prevalence of the Absence of Cirrhosis in Subjects with NAFLD-Associated Hepatocellular Carcinoma
    Marco Castellana, Rossella Donghia, Luisa Lampignano, Fabio Castellana, Roberta Zupo, Rodolfo Sardone, Giovanni De Pergola, Gianluigi Giannelli · 2021 · Journal of Clinical Medicine
37. Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)
    Associazione Italiana per lo Studio del Fegato (AISF), Società Italiana di Diabetologia (SID) and Società Italiana dell’Obesità (SIO) · 2021 · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity
38. Advancing Surveillance Strategies for Hepatocellular Carcinoma: A New Era of Efficacy and Precision
    Amit G. Singal, Michelle Ng, Anand L Kulkarni · 2024 · Journal of Clinical and Experimental Hepatology
39. Estimates and trends of the global burden of NASH-related liver cancer attributable to high fasting plasma glucose in 1990–2019: analysis of data from the 2019 Global Burden of Disease Study
    Ziyi Li, Na Yang, Liyun He, Jialu Wang, Fan Ping, Wei Li, Lingling Xu, Huabing Zhang, Yuxiu Li · 2023 · Diabetology & Metabolic Syndrome
40. CDH11 promotes liver fibrosis via activation of hepatic stellate cells
    Wanyuan Ruan, Runsang Pan, Xiaoxu Shen, Yingjie Nie, Wu Yayun · 2018 · Biochemical and Biophysical Research Communications
41. LCR1 and LCR2, two multi‐analyte blood tests to assess liver cancer risk in patients without or with cirrhosis
    Thierry Poynard, Valentina Peta, Olivier Deckmyn, Mona Munteanu, Joseph Moussalli, Yen Ngo, Marika Rudler, Pascal Lebray, Raluca Pais, Luminita Bonyhay et al. · 2018 · Alimentary Pharmacology & Therapeutics
42. mTOR Activation in Liver Tumors Is Associated with Metabolic Syndrome and Non-Alcoholic Steatohepatitis in Both Mouse Models and Humans
    Takahiro Okuno, Anna Kakehashi, Naomi Ishii, Masaki Fujioka, Min Gi, Hideki Wanibuchi · 2018 · Cancers
43. Improved survival after treatments of patients with nonalcoholic fatty liver disease associated hepatocellular carcinoma
    Jihane N. Benhammou, Elizabeth S. Aby, Gayaneh Shirvanian, Kohlett Manansala, Shehnaz K. Hussain, Myron John Tong · 2020 · Scientific Reports
44. Lifestyle and Pharmacologic Approaches to Prevention of Metabolic Dysfunction-associated Steatotic Liver Disease-related Hepatocellular Carcinoma
    Makan Cheraghpour, Behzad Hatami, Amit G. Singal · 2025 · Clinical Gastroenterology and Hepatology
45. Metabolic dysfunction-associated steatotic liver disease (MASLD): a systemic disease with a variable natural history and challenging management
    Luigi Elio Adinolfi, Aldo Marrone, Luca Rinaldi, Riccardo Nevola, Antonio Izzi, Ferdinando Carlo Sasso · 2025 · Exploration of Medicine
46. Key features of the environment promoting liver cancer in the absence of cirrhosis
    Marco Y. W. Zaki, A. K. Mahdi, G. Patman, A. Whitehead, João P. Maurício, M. McCain, D. Televantou, Sameh Abou-Beih, E. Ramon‐Gil, R. Watson et al. · 2021 · Scientific Reports
47. The Implications of Noncoding RNAs in the Evolution and Progression of Nonalcoholic Fatty Liver Disease (NAFLD)-Related HCC
    Rusu, Ioana, Pirlog, Radu, Chiroi, Paul, Nutu, Andreea, Puia, Vlad Radu, Fetti, Alin Cornel, Rusu, Daniel Radu, Berindan-Neagoe, Ioana, Al Hajjar, Nadim · 2022 · International Journal of Molecular Sciences
48. Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma
    Simona Cernea, Danusia Maria Onișor · 2023 · World Journal of Gastroenterology
49. Serum Fibroblast Growth Factor 21 Is Markedly Decreased following Exercise Training in Patients with Biopsy-Proven Nonalcoholic Steatohepatitis
    Jonathan G. Stine, Jaclyn E. Welles, Shelley Elizabeth Keating, Zeba Hussaini, Christopher T. Soriano, J. Wes Heinle, Nathaniel R. Geyer, Vernon M. Chinchilli, Rohit Seth Loomba, Scot R. Kimball · 2023 · Nutrients
50. Hepatocellular Cancer Surveillance in Patients with Advanced Chronic Liver Disease
    Wen Gu, Victor de Lédinghen, Christophe Aubé, Aleksander Ahm Krag, Christian P. Strassburg, Laurent Castéra, Jérôme Dumortier, Mireen Friedrich‐Rust, Stanislas Pol, Ivica Grgurević et al. · 2024 · NEJM Evidence
51. Risk-stratified hepatocellular carcinoma surveillance in non-cirrhotic patients with MASLD
    Ke Mi, Tingdan Ye, Lin Zhu, Calvin Q. Pan · 2025 · Gastroenterology report
52. Translational Control of Metabolism and Cell Cycle Progression in Hepatocellular Carcinoma
    Alessandra Scagliola, Annarita Miluzio, Stefano Biffo · 2023 · International Journal of Molecular Sciences
53. The Prevalence and Determinants of NAFLD and MAFLD and Their Severity in the VA Primary Care Setting
    Aaron P. Thrift, Theresa Hoang-Anh Nguyen, Codey Pham, Maya Balakrishnan, Fasiha Kanwal, Rohit Seth Loomba, Hao T. Duong, David J. Ramsey, Hashem B. El‐Serag · 2022 · Clinical Gastroenterology and Hepatology
54. Spontaneously Ruptured Hepatocellular Carcinoma: Computed Tomography-Based Assessment
    Fabio Sandomenico, Valerio Arpaia, Ferdinando De Rosa, Orlando Catalano, Roberto Buonaiuto, Marianna Notarangelo, Maria Iovino, Sabrina Giovine, Arturo Brunetti, Mariano Scaglione · 2023 · Diagnostics
55. Meeting at the Crossroad between Obesity and Hepatic Carcinogenesis: Unique Pathophysiological Pathways Raise Expectations for Innovative Therapeutic Approaches
    Konstantinos Arvanitakis, Stavros P. Papadakos, Vasileios Lekakis, Theocharis Koufakis, Ioannis G. Lempesis, Eleni Papantoniou, Georgios Kalopitas, Vasiliki Epameinondas GEORGAKOPOULOU, Ioanna Ε. Stergiou, Stamatios E Theocharis et al. · 2023 · International Journal of Molecular Sciences
56. MASLD-Related Hepatocarcinoma: Special Features and Challenges
    Carmen Yagüe Caballero, Diego Casas Deza, Silvia Espina, Andrea Pascual Oliver, José Miguel Arbonés-Mainar, Vanesa Bernal Monterde · 2024 · Journal of Clinical Medicine
57. The diagnostic and initial approach of the patient with non-alcoholic fatty liver disease: role of the primary care provider.
    Nicolás Salva-Pastor, Norberto Carlos Chávez-Tapia, Misael Uribe, Natalia Nuño‐Lámbarri · 2019 · Gastroenterology and hepatology from bed to bench.
58. 18F-fludeoxyglucose positron emission tomography for diagnosis of HCC: implications for therapeutic strategy in curative and non-curative approaches
    Arno Kornberg, Helmut Friess · 2019 · Therapeutic Advances in Gastroenterology
59. The association of nonalcoholic steatohepatitis and hepatocellular carcinoma
    Mohammad Maysara Asfari, Muhammad Talal Sarmini, Mohammad Alomari, Rocío López, Srinivasan Dasarathy, Arthur J. McCullough · 2020 · European Journal of Gastroenterology & Hepatology
60. Hepatocellular carcinoma-the role of the underlying liver disease in clinical practice
    Ângelo Zambam de Mattos, Isadora Bombassaro, Arndt Vogel, José Daniel Debes · 2024 · World Journal of Gastroenterology
61. The Changing Demographics and Epidemiology of Hepatocellular Carcinoma
    Rushabh Gujarathi, Jeremy A. Klein, Chih‐Yi Liao, Anjana A Pillai · 2024 · Clinics in Liver Disease
62. The increasing clinical burden of NAFLD in Asia
    Marianne Anastasia De Roza, George Boon‐Bee Goh · 2019 · The Lancet. Gastroenterology & hepatology
63. Liver Fibrosis in Non-Alcoholic Fatty Liver Disease and Progression to Hepatocellular Carcinoma in Patients with Inflammatory Bowel Disease: A Systematic Review
    Samuel J. Martínez‐Domínguez, Sandra G. García, Viviana Laredo, Carla J. Gargallo-Puyuelo, Beatriz Gallego Llera, Julia López de la Cruz, Fernando Gomollón · 2023 · Cancers
64. Lack of response to immunotherapy in non-alcoholic steatohepatitis related hepatocellular carcinoma.
    M. Kudo · 2021 · Hepatobiliary surgery and nutrition
65. The Neglected Role of Bile Duct Epithelial Cells in NASH
    Massimiliano Cadamuro, Alberto Lasagni, Samantha Sarcognato, Maria Guido, Roberto Fabris, Mario Strazzabosco, Alastair J. Strain, Paolo Simioni, Erica Villa, Luca Fabris · 2021 · Seminars in Liver Disease
66. Cirrhosis, a Global and Challenging Disease
    José Ignacio Fortea, Javier Crespo, Ángela Puente · 2022 · Journal of Clinical Medicine
67. Identifying a distinct fibrosis subset of NAFLD via molecular profiling and the involvement of profibrotic macrophages
    Weiwei He, Yinxiang Huang, Xiulin Shi, Qingxuan Wang, Menghua Wu, Han Li, Qiuhong Liu, Xiaofang Zhang, Caoxin Huang, Xuejun Li · 2023 · Journal of Translational Medicine
68. Apoptosis antagonizing transcription factor‐mediated liver damage and inflammation to cancer: Therapeutic intervention by curcumin in experimental metabolic dysfunction associated steatohepatitis‐hepatocellular carcinoma
    Akshatha N. Srinivas, Diwakar Suresh, Saravana Babu Chidambaram, Prasanna K. Santhekadur, Divya P. Kumar · 2023 · Journal of Cellular Physiology
69. Epidemiology of metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-related liver disease (ALD)
    Robert J. Wong · 2024 · Metabolism and Target Organ Damage
70. Hepatocellular Carcinoma Screening: From Current Standard of Care to Future Directions
    Michael Mohnasky, Sandra Gad, Andrew M. Moon, Alfred Sidney Barritt, Resmi Ann Charalel, Caroline Eckblad, Andrew Caddell, Minzhi Xing, Nima Kokabi · 2025 · Journal of the American College of Radiology
71. Hepatocellular carcinoma in nonalcoholic fatty liver disease: A growing challenge
    Â. Mattos, J. Debes, R. Dhanasekaran, J. Benhammou, M. Arrese, André Luiz V. Patrício, A. C. Zilio, Angelo A. Mattos · 2021 · World Journal of Hepatology
72. Surveillance for hepatocellular carcinoma: current status and future perspectives for improvement
    Bernardo Stefanini, Matteo Tonnini, Ilaria Serio, Matteo Renzulli, Francesco Tovoli · 2022 · Expert Review of Anticancer Therapy
73. Comparison of effectiveness and safety of camrelizumab between HBV-related and non-B, non-C hepatocellular carcinoma: A retrospective study in China
    Haonan Liu, Xiaobing Qin, Zhiyuan Xu, Meng Yin Wu, Tong Lu, Shuang Ying Zhou, Nan Yao, Suya Liu, Yong Shao, Zhengxiang Han · 2022 · Frontiers in Genetics
74. Exploring Opportunities to Enhance the Screening and Surveillance of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease (NAFLD) through Risk Stratification Algorithms Incorporating Ultrasound Elastography
    Mădălina-Gabriela Țâru, Monica Lupșor‐Platon · 2023 · Cancers
75. Ultrasound evaluation of chronic liver disease
    Giovanna Ferraioli, Richard G. Barr · 2024 · Abdominal Radiology
76. Hepatocellular Carcinoma
    Anisha Jain, Benjamin L. Mazer, Yanhong Deng, Maria M. Ciarleglio, Dhanpat Jain, Tamar Hamosh Taddei, Xuchen Zhang · 2021 · American Journal of Clinical Pathology
77. Preventive strategy for nonalcoholic fatty liver disease-related hepatocellular carcinoma
    Yuri Cho, Bo Hyun Kim, Joong‐Won Park · 2022 · Clinical and Molecular Hepatology
78. Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Facts and Hopes
    Luigi Elio Adinolfi, Aldo Marrone, Antonio Izzi, Antonio Craxı̀ · 2025 · Journal of Clinical and Experimental Hepatology
79. Holistic Approach in the Management of Nonalcoholic Fatty Liver Disease
    Ananta Shrestha, Shrijana Pradhananga · 2022 · Euroasian Journal of Hepato-Gastroenterology
80. Navigating the Nomenclature of Liver Steatosis: Transitioning from NAFLD to MAFLD and MASLD - Understanding Affinities and Differences
    Apichat Kaewdech, Pimsiri Sripongpun · 2024 · Siriraj Medical Journal/San Sirirat
81. Killing hepatocellular carcinoma in the NAFLD/NASH stage: a comprehensive perspective on targeting regulated cell death
    Jianxin Xi, Shuang-Yin Lei, Jie Chen, Jiahui Liu, Chenhao Shan, Xun Sun, Qianqian Zheng, Xiaoju Shi · 2025 · Cell Death Discovery
82. Hepatocellular carcinoma in non-alcoholic fatty liver disease with and without cirrhosis
    Georgia Onzi, Fernanda Moretti, Silvana Sartori Balbinot, Raul Ângelo Balbinot, Jonathan Soldera · 2019 · Hepatoma Research
83. The role of immune cells in the liver tumor microenvironment: an involvement of gut microbiota-derived factors
    Tomonori Kamiya, Naoko Ohtani · 2022 · International Immunology
84. Contribution of organokines in the development of NAFLD/NASH associated hepatocellular carcinoma
    Meenakshi Vachher, Savita Bansal, Bhupender Kumar, Sandeep Yadav, Taruna Katyal Arora, Nalini Moza Wali, Archana Burman · 2022 · Journal of Cellular Biochemistry
85. Clinical features and management issues of NAFLD-related HCC: what we know so far
    Nicola Pugliese, Ludovico Alfarone, Ivan Arcari, Silvia Giugliano, Tommaso Lorenzo Parigi, María Rescigno, Ana Lleò, Alessio Aghemo · 2022 · Expert Review of Gastroenterology & Hepatology
86. Clinical characteristics of metabolic associated fatty liver disease (MAFLD) in subjects with myotonic dystrophy type 1 (DM1)
    Luca Miele, Alessia Perna, Marianxhela Dajko, Maria Assunta Zocco, Antonio De Magistris, Tommaso Filippo Nicoletti, Marco Biolato, Giuseppe Marrone, Antonio Liguori, Daria Maccora et al. · 2021 · Digestive and Liver Disease
87. Common Denominator of MASLD and Some Non-Communicable Diseases
    Katarzyna Ferenc, Sara Jarmakiewicz-Czaja, Aneta Sokal-Dembowska, Katarzyna Stasik, Rafał Filip · 2024 · Current Issues in Molecular Biology
88. Carcinome Hépatocellulaire (CHC)
    Stanislas Pol · 2024 · Médecine tropicale et santé internationale
89. Non-alcoholic fatty liver disease-related hepatocellular carcinoma: Is there a role for immunotherapy?
    Â. Mattos, Jose D. Debes, Arndt Vogel, M. Arrese, Xavier S. Revelo, T. H. S. Pase, Muriel Manica, Angelo A. Mattos · 2022 · World Journal of Gastroenterology
90. Pearls and pitfalls in non-alcoholic fatty liver disease: tricky results are common
    Brian J. Wentworth, Stephen Hugh Caldwell · 2021 · Metabolism and Target Organ Damage
91. Insight into the regulatory mechanism of m6A modification: From MAFLD to hepatocellular carcinoma
    Xuan Zha, Zewei Gao, Min Li, Xueli Xia, Zhenwei Mao, Shengjun Wang · 2024 · Biomedicine & Pharmacotherapy
92. Network Pharmacology and Molecular Docking Study on the Multi-Target Mechanisms of Aloe vera for Non-Alcoholic Steatohepatitis Treatment
    Tấn Khanh Nguyễn, Huy Hieu Phung, Won Jun Choi, Hee‐Chul Ahn · 2022 · Plants
93. A study of 3013 cases of hepatocellular carcinoma: Etiology and therapy before and during the current decade
    Miao Shan Lim, George Boon‐Bee Goh, Jason Pik-Eu Chang, JeeKeem Low, Vishal Girishchandra Shelat, Terence Cheong Wei Huey, Yock-Young Dan, Alfred Wei Chieh Kow, Shridhar Ganpathi Iyer, Poh-Seng Tan et al. · 2021 · JGH Open
94. Patients with Nonalcoholic Steatohepatitis and Advanced Liver Disease Have the Lowest Cardiorespiratory Fitness
    Jessica Dahmus, Breianna L. Hummer, Gloriany Rivas, Kathryn H. Schmitz, Stephen Hugh Caldwell, Curtis Kent Argo, Ian Roy Schreibman, Jonathan G. Stine · 2023 · Digestive Diseases and Sciences
95. Changes in the Epidemiology of Hepatocellular Carcinoma in Carinthia, Austria, 2012–2023
    Florian Hucke, Heleen Emmer, Roberto Emmer, Miriam Hucke, Simona I. Bota, Matthias Fürstner, Klaus Armin Hausegger, Reinhard P. Mittermair, Markus Peck‐Radosavljevic · 2023 · Cancers
96. Elevated enteric putrescine suppresses differentiation of intestinal germinal center B cells
    Xia Wei, Shaojie Shi, Zixuan Lu, Chengyu Li, Xiangping Xu, Jinquan Chai, Xiaofei Liu, Tao Hu, Bin Wang · 2024 · International Immunopharmacology
97. Older Age But Not Comorbidity Is Associated With Worse Survival in Patients With Hepatocellular Carcinoma
    Mounika Kanneganti, Mohammed Al-Hasan, Samantha Bourque, Sneha Deodhar, Ju Dong Yang, Daniel Q. Huang, Anand V. Kulkarni, Purva Gopal, Neehar D. Parikh, Fasiha Kanwal et al. · 2024 · Clinical Gastroenterology and Hepatology
98. MASH to cirrhosis: bridging the gaps in MASLD management
    Zouhir Gadi, Wilhelmus Josephus Kwanten, Luisa Vonghia, Sven Francque · 2024 · Acta Clinica Belgica
99. Metabolic dysfunction-associated steatotic liver disease and its associated health risks
    Xia-Rong Liu, Szu‐Ching Yin, Yi-Ting Chen, Mei–Hsuan Lee · 2025 · Journal of the Chinese Medical Association
100. Hepatitis C and Nonalcoholic Steatohepatitis in the 21st Century: Impact on Liver Disease and Liver Transplantation
     Sonia Samuel, Ahmad Abulawi, Raza Malik · 2023 · Gastroenterology Insights